Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5

ABSTRACT: Objectives: Bebtelovimab is an anti-SARS-CoV-2 monoclonal antibody active against Omicron lineage variants authorized to treat high-risk outpatients with COVID-19. We sought to determine the real-world effectiveness of bebtelovimab during the Omicron phases BA.2/BA2.12.1/BA4/BA5. Methods:...

Full description

Bibliographic Details

Main Authors:	Kyle C. Molina, Victoria Kennerley, Laurel E. Beaty, Tellen D. Bennett, Nichole E. Carlson, David A. Mayer, Jennifer L. Peers, Seth Russell, Matthew K. Wynia, Neil R. Aggarwal, Adit A. Ginde
Format:	Artigo
Language:	Inglês
Published:	Elsevier 2023-07-01
Series:	International Journal of Infectious Diseases
Subjects:	Anti-SARS-COV-2 monoclonal antibody COVID-19 Outpatient Nonhospitalized LY-CoV1404
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971223005258
Tags:	Add Tag No Tags, Be the first to tag this record!